Peripheral Artery Disease Market Report: Market Size & Forecast 2026

The Peripheral Artery Disease market covers a broad treatment landscape spanning pharmaceutical interventions, surgical revascularization, and minimally invasive endovascular procedures to address arterial blockages caused primarily by atherosclerosis. Market valuations in 2025-2026 range across sources from approximately $4.6 billion to $5.5 billion, with longer-term projections extending beyond $11 billion by the mid-2030s under various CAGR assumptions. The market includes both established treatment paradigms and emerging technologies targeting improved long-term patency and patient outcomes.

• •PAD affects an estimated 200-300 million people globally, with prevalence rising sharply above age 50
• •The disease imposes a substantial economic burden driven by hospitalization costs and long-term disease management
• •Market scope spans drug-eluting devices, stents, atherectomy systems, anticoagulants, and adjunctive wound-care products

An aging global population, rising rates of diabetes and tobacco use, and greater clinical awareness of PAD are expanding the treatable patient pool across both developed and emerging markets. Advancements in minimally invasive endovascular techniques are broadening eligibility beyond patients suitable for traditional open surgical approaches. Reimbursement expansions in major healthcare markets are improving patient access to newer interventional technologies.

• •Rising prevalence of diabetes and metabolic syndrome is a primary epidemiological driver, particularly in emerging economies
• •Growing adoption of drug-coated balloons, atherectomy devices, and bioresorbable technology platforms is shifting treatment patterns
• •Increased screening programs and earlier clinical diagnosis are expanding the addressable patient population

The market is typically segmented by product type into devices, drug therapies, and surgical procedures, with endovascular devices representing the fastest-growing category. Geographically, North America accounts for the largest share due to high disease prevalence, advanced healthcare infrastructure, and favorable reimbursement frameworks, while Asia-Pacific is projected to exhibit the strongest growth rates driven by aging populations and expanding medical access.

• •Japan alone represented an estimated $387 million of the regional market in 2023, reflecting a mature but steadily growing market
• •Europe holds a significant share supported by widespread screening programs, epidemiological surveillance, and centralized healthcare systems
• •Emerging markets in Latin America and the Middle East are projected to gain share as healthcare spending and vascular intervention capacity increase

Who are the notable companies in the industry?

The market features a competitive structure spanning large diversified medical technology firms to specialized mid-tier players focused exclusively on peripheral interventions. Boston Scientific Corporation, Becton, Dickinson and Company, Medtronic plc, Abbott Laboratories, and Edwards Lifesciences Corporation represent the major diversified operators in this space, while Cardinal Health Inc., Vascular Solutions Inc., and Bayer AG join them as key participants across the landscape. Collectively, these eight companies hold the largest market share and set industry trends, operating at varying integration levels, some across the full value chain from materials and manufacturing through finished device assembly and distribution, others on narrower technology platforms. All are active in the management and treatment of Peripheral Artery Disease, offering medical devices, medications, and interventional therapies to address the condition's symptoms and complications. The industry remains moderately fragmented, with no single participant commanding a dominant share, reflecting the diversity of device types, therapeutic approaches, and regional regulatory requirements that define this growing sector.

• •Primary technology and process routes include balloon angioplasty, stenting, atherectomy, and drug-coated devices, each requiring distinct manufacturing and material science capabilities
• •Manufacturing and R&D capacity is concentrated in regions with established medical device ecosystems, particularly North America, Western Europe, and parts of East Asia
• •Innovation is driven by specialization in specific procedural technologies rather than broad horizontal product portfolios

What are the recent trends and outlook?

The market is shifting toward more personalized treatment algorithms that leverage intravascular imaging and physiologic assessment tools to improve long-term vessel patency rates. Regulatory pathways for next-generation devices and drug-device combination products are becoming more harmonized across major markets, facilitating faster commercialization. Continued portfolio expansion through mergers, acquisitions, and licensing agreements is expected as participants seek to broaden their peripheral vascular offerings.

• •A shift toward outpatient and ambulatory surgical center settings is reducing procedural costs and expanding geographic access to treatment
• •Artificial intelligence-assisted planning tools and advanced imaging guidance represent emerging technology frontiers in the market
• •Long-term outlook supports sustained mid-single-digit annual growth through 2034 and beyond as aging demographics persist